4072-32-6

Basic information

• Product Name: methyl 3-(6-hydroxy-5,7,8-trimethyl-chroman-2-yl)propanoate
• Synonyms: alpha-CEHC;methyl 3-(6-hydroxy-5,7,8-trimethyl-chroman-2-yl)propanoate;2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman;AXODOWFEFKOVSH-UHFFFAOYSA-N
• CAS NO: 4072-32-6
• Molecular Formula: C16H22O4
• Molecular Weight: 278.3435
• Mol File: 4072-32-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 474.9°Cat760mmHg
• Flash Point: 174.4°C
• Appearance: /
• Density: 1.151g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.546
• CAS DataBase Reference: methyl 3-(6-hydroxy-5,7,8-trimethyl-chroman-2-yl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(6-hydroxy-5,7,8-trimethyl-chroman-2-yl)propanoate(4072-32-6)
• EPA Substance Registry System: methyl 3-(6-hydroxy-5,7,8-trimethyl-chroman-2-yl)propanoate(4072-32-6)

Safety Data

• Hazardous Substances Data: 4072-32-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H22O4/c1-9-10(2)15-12(11(3)14(9)19)5-7-16(4,20-15)8-6-13(17)18/h19H,5-8H2,1-4H3,(H,17,18)

Upstream product

• 1088428-42-5 α-CEHC sulfate trimethylamine 
• 1073-11-6 5-methyl-5-vinyl-dihydro-furan-2-one 
• 700-13-0 Trimethylhydroquinone 

Downstream Products

• 3121-68-4 2,3,5-trimethyl-6-(2-(2-methyl-5-oxotetrahydrofuran-2-yl)ethyl)cvclohexa-2,5-diene-1,4-dione 

Relevant articles and documents

Isolation and identification of α-CEHC sulfate in rat urine and an improved method for the determination of conjugated α-CEHC

2,5,7,8-Tetramethyl-2-(2′-carboxyethyl)-6-hydroxychroman (α-CEHC), the water-soluble metabolite of α-tocopherol (α-TOH) with a shortened side chain but an intact hydroxychroman structure, has been identified in human urine and are thought to be produced in significant amount at excess intake of α-TOH. In previous studies, CEHCs in biological specimens were measured by HPLC, GC-MS or LC-MS, preceded by a hydrolysis procedure using either enzyme or methanolic HCl. In an attempt to analyze α-CEHC in rat urine accordingly, we observed that enzyme hydrolysis was relatively inefficient in releasing α-CEHC compared to high concentrations of HCl. The HCl releasable α-CEHC conjugate was isolated and chemically identified as 6-O-sulfated α-CEHC (α-CEHC sulfate). Using the synthetic α-CEHC sulfate standard, it was found that sulfatase could not hydrolyze to a significant extent. On the other hand, pretreatment with HCl at 60°C in the presence of ascorbate, followed by a one-step ether extraction, not only hydrolyzed the sulfate conjugate completely but also extracted α-CEHC with high recovery. The inclusion of ascorbate minimized the conversion of α-CEHC to α-tocopheronolactone in the HCl pretreatment. A complete procedure for the quantitative analysis of α-CEHC including HCl hydrolysis, ether extraction and reverse phase isocratic HPLC-ECD was thus established. In conclusion, α-CEHC sulfate was isolated and identified as the HCl-releasable conjugate of α-CEHC in rat urine. A rapid and sensitive method with high reproducibility for the determination of free, conjugated and total α-CEHC is then established.

Chroman derivatives for the reduction of inflammation symptoms

The present invention provides a composition comprising chroman derivatives, for use in the reduction of inflammatory markers associated with inflammation, particularly for the reduction of C-reactive protein (CRP) and for use in the treatment and/or amelioration of symptoms of inflammation.